glp-1 receptor agonists in idiopathic intracranial hypertension are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read NeuroOp Guru: Stopping GLP-1 therapy

After you confirm all the order details, pay 100% in advance and give us the delivery address

Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population

For readers who want to browse related options, the Natural Immunity Supplements collection is worth exploring

Nebuwa C, Omoike OJ, Fagbenro A, Uwumiro F, Erhus E, Okpujie V, et al

Apply for a wholesale account with us here.